ZA201807446B - Improved drug formulations - Google Patents

Improved drug formulations

Info

Publication number
ZA201807446B
ZA201807446B ZA2018/07446A ZA201807446A ZA201807446B ZA 201807446 B ZA201807446 B ZA 201807446B ZA 2018/07446 A ZA2018/07446 A ZA 2018/07446A ZA 201807446 A ZA201807446 A ZA 201807446A ZA 201807446 B ZA201807446 B ZA 201807446B
Authority
ZA
South Africa
Prior art keywords
drug formulations
improved drug
methods
improved
sprying
Prior art date
Application number
ZA2018/07446A
Other languages
English (en)
Inventor
Dave A Miller
Daniel J Ellenberger
Sandra U Schilling
Original Assignee
Dispersol Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dispersol Technologies Llc filed Critical Dispersol Technologies Llc
Publication of ZA201807446B publication Critical patent/ZA201807446B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2018/07446A 2016-05-09 2018-11-06 Improved drug formulations ZA201807446B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333482P 2016-05-09 2016-05-09
US201662334576P 2016-05-11 2016-05-11
PCT/US2017/031521 WO2017196712A1 (en) 2016-05-09 2017-05-08 Improved drug formulations

Publications (1)

Publication Number Publication Date
ZA201807446B true ZA201807446B (en) 2025-05-28

Family

ID=60267508

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/07446A ZA201807446B (en) 2016-05-09 2018-11-06 Improved drug formulations

Country Status (10)

Country Link
US (1) US20200009060A1 (enExample)
EP (2) EP4552641A3 (enExample)
JP (2) JP7112333B2 (enExample)
CN (1) CN109069460A (enExample)
AU (1) AU2017262586B2 (enExample)
CA (1) CA3022878C (enExample)
IL (1) IL262745B (enExample)
MA (1) MA44987A (enExample)
WO (1) WO2017196712A1 (enExample)
ZA (1) ZA201807446B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂
WO2021086565A1 (en) * 2019-11-01 2021-05-06 Dispersol Technologies, Llc Weakly basic drug and ionic polymer pharmaceutical formulations and methods of formation and administration thereof
KR20220123689A (ko) * 2020-03-11 2022-09-08 사와이세이야쿠 가부시키가이샤 과립 및 그것을 이용한 제제
WO2022094817A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
NL2028762B1 (en) * 2021-07-16 2023-01-23 Seranovo Holding B V Micelle-generating formulations for enhanced bioavailability
CN116173018A (zh) * 2021-11-26 2023-05-30 上海宣泰医药科技股份有限公司 一种达罗他胺药物组合物及其制备方法和用途
CN114190538B (zh) * 2021-12-21 2023-11-24 郑州轻工业大学 一种促β′晶型形成的油脂促结晶剂及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990044257A (ko) * 1996-05-20 1999-06-25 디르크 반테 생체이용율이 개선된 항진균성 조성물
CN101494979A (zh) * 2006-03-20 2009-07-29 沃泰克斯药物股份有限公司 药物组合物
CA2990445C (en) 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
EP2259777A2 (en) * 2008-02-28 2010-12-15 BIAL - Portela & Ca., S.A. Pharmaceutical composition for poorly soluble drugs
WO2009132208A1 (en) * 2008-04-24 2009-10-29 Evestra, Inc. Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen
US20110065800A1 (en) * 2008-05-14 2011-03-17 Haihong Fan Formulations for cathepsin k inhibitors
CA2799110A1 (en) * 2010-05-10 2011-11-17 Evonik Roehm Gmbh Pharmaceutical dosage form comprising one or more antiretroviral active ingredients
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
US8591944B2 (en) * 2011-03-08 2013-11-26 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2014170026A1 (en) * 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
HUE057232T2 (hu) * 2014-04-18 2022-04-28 Dispersol Technologies Llc Többsebességes eljárás és keverõ termokinetikusan ömlesztve elegyített sarzs hõérzékeny részeinek megõrzésére
WO2015175505A1 (en) * 2014-05-15 2015-11-19 Lundbeck Llc Tetrabenazine modified release formulation
WO2016073421A1 (en) * 2014-11-03 2016-05-12 Dispersol Technologies, Llc Improved formulations of vemurafenib and methods of making the same
CN104434809B (zh) * 2014-12-10 2018-10-16 北京科莱博医药开发有限责任公司 一种奥拉帕尼固体分散体制剂及其制备方法
BR102017011025A2 (pt) * 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds

Also Published As

Publication number Publication date
IL262745B (en) 2022-07-01
JP7458440B2 (ja) 2024-03-29
JP7112333B2 (ja) 2022-08-03
EP3454847A1 (en) 2019-03-20
CA3022878C (en) 2024-04-30
EP4552641A3 (en) 2025-07-30
MA44987A (fr) 2019-03-20
AU2017262586B2 (en) 2023-04-13
CN109069460A (zh) 2018-12-21
EP4552641A2 (en) 2025-05-14
JP2022116234A (ja) 2022-08-09
CA3022878A1 (en) 2017-11-16
IL262745A (en) 2018-12-31
JP2019514993A (ja) 2019-06-06
AU2017262586A1 (en) 2018-11-22
US20200009060A1 (en) 2020-01-09
WO2017196712A1 (en) 2017-11-16
EP3454847A4 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
ZA201807446B (en) Improved drug formulations
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
UA122498C2 (uk) Біциклічні похідні, спосіб їх отримання та фармацевтичні композиції, що їх містять
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
CA2989145C (en) IMPROVED DEFERASIROX FORMULATIONS AND THEIR MANUFACTURING PROCESSES
MX2020011478A (es) Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos.
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
PH12018502615A1 (en) Depot formulations
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
EP3103453A4 (en) Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient
EP4509178A3 (en) High purity oritavancin and method of producing same
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
MX345263B (es) Formulación de pexiganan estable.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
PH12019500024A1 (en) Pharmaceutical compositions
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
MX393915B (es) Nuevas formulaciones orales de belinostat.
WO2017210527A8 (en) Autotaxin inhibitors
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MX2019000977A (es) Composiciones farmacéuticas a base de curcumina y procedimientos para su fabricación.
HK40025095A (en) Nanoparticle compositions, methods of fabrication, and use for drug delivery
HK1240487A1 (en) Methods for formulating antibody drug conjugate compositions